Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Humana (HUM) PT Raised to $410 at Cantor Fitzgerald
-
Orchid Island Capital Announces June 2020 Monthly Dividend and May 31, 2020 RMBS Portfolio Characteristics
-
Provention Bio Inc. (PRVB) Announces Proposed 5.5M Share Common Offering
-
Provention Bio Announces Proposed Public Offering of Common Stock
-
Charlotte's Web Holdings (CWEB:CN) (CWBHF) PT Lowered to $5.85 at Cantor Fitzgerald
-
Pre-Open Stock Movers 06/16: (IDYA) (IQ) (HEAR) Higher; (IZEA) (CLDX) (CHK) Lower (more...)
-
Companies with NDRs 6/16
-
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019
-
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019
-
Celldex (CLDX) Prices 13.378M Share Common Offering at $9.75/Sh
-
Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock
-
After-Hours Stock Movers 06/15: (WW) (MBIO) (VRAY) Higher; (CLDX) (AVEO) (AAXN) Lower (more...)
-
UPDATE: Cantor Fitzgerald Assumes ViewRay Inc. (VRAY) at Overweight
-
UPDATE: Cantor Fitzgerald Assumes RTI Biologics (RTIX) at Overweight
-
UPDATE: Cantor Fitzgerald Assumes SI-BONE Inc. (SIBN) at Overweight, Top Pick
-
UPDATE: Cantor Fitzgerald Assumes SeaSpine Holdings (SPNE) at Overweight
-
UPDATE: Cantor Fitzgerald Assumes Cerus (CERS) at Overweight
-
UPDATE: Cantor Fitzgerald Assumes AxoGen, Inc. (AXGN) at Overweight
-
Celldex (CLDX) Announces Proposed Common Share Offering
-
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
-
Amarin (AMRN) Continues to Offer 'Sweets' - Cantor Fitzgerald
-
Companies with NDRs 6/15
-
UPDATE: Cantor Fitzgerald Starts Selectquote (SLQT) at Overweight
-
Pacific Biosciences of California (PACB) CEO Discusses Departure and Shelf Filing -Cantor Fitzgerald
-
Celldex Therapeutics (CLDX) PT Raised to $12 at Cantor Fitzgerald After Positive CDX-0159 Data
-
Mustang Bio (MBIO) Prices 10.79M Share Common Offering at $3.25/Sh
-
Mustang Bio Announces Pricing of Public Offering of Common Stock
-
Mustang Bio Announces Pricing of Public Offering of Common Stock
-
Companies with NDRs 6/11
-
Affimed (AFMD) Announces Angus Smith as CFO
-
Affimed Announces Appointment of Angus Smith as Chief Financial Officer
-
Affimed Announces Appointment of Angus Smith as Chief Financial Officer
-
Mustang Bio (MBIO) to Offer Common Stock
-
Mustang Bio Announces Proposed Public Offering of Common Stock
-
Mustang Bio Announces Proposed Public Offering of Common Stock
-
Hexo Corp. (HEXO:CN) (HEXO) PT Raised to Cdn$0.90 at Cantor Fitzgerald
-
Pacific Biosciences of California (PACB) Management Change Could Be a Fresh Start - Cantor Fitzgerald
-
Pre-Open Stock Movers 06/09: (NKLA) (LOVE) (M) Higher; (SLNO) (CHK) (CERC) Lower (more...)
-
Cantor Fitzgerald Raises Estimates for 2Q on Anthem's (ANTM) 8-K
-
Makor Group Grows Amid COVID-19 Crisis, Expands Derivatives Desk in Europe
-
After-Hours Stock Movers 6/8: (M) (CFRX) (SMG) HIGHER; (SLNO) (CHK) (CERC) LOWER (more...)
-
Cantor Fitzgerald Starts ContraFect Corp. (CFRX) at Overweight
-
Acacia Research Enhances Senior Management Team, Names Richard Rosenstein as CFO, Meredith Simmons as General Counsel
-
SolGold PLC Announces Results of Placing
-
Cantor Fitzgerald Starts Fennec Pharmaceuticals Inc. (FENC) at Overweight
-
Change Healthcare Inc. (CHNG) PT Lowered to $17 at Cantor Fitzgerald, Following Earnings
-
SolGold PLC Announces Proposed Fundraising
-
Cantor Fitzgerald Reiterates Overweight Rating on Health Catalyst Inc. (HCAT) Following Investor Meetings
-
Mereo BioPharma Announces Completion of $70 Million Private Placement
-
Mereo BioPharma Announces Completion of $70 Million Private Placement

